International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology

• DOI: 10.1016/j.kint.2023.03.007
• Publication Date: 2023-03-28T01:01:10Z
• Authors: Masaomi Nangaku; A. Richard Kitching; Peter Boor; Alessia Fornoni; Jürgen Floege; P. Toby Coates; Jonathan Himmelfarb; Rachel Lennon; Hans-Joachim Anders; Benjamin D. Humph...; Fergus J. Caskey; Agnes B. Fogo; Andrea Angeletti; Patricia W. Bedard; Ariela Benigni; Anna Björnson Gra...; Vera Certikova Ch...; Christos Chatzian...; Rolando Claure-De...; Jennifer Cross; Sandrine Damster; Jo-Ann Donner; Frank Eitner; Stanislas Faguer; Antonio Fontanella; Yuri Fujimoto; Joseph Gaut; Leslie Gewin; Pernille B.L. Hansen; John Cijiang He; Jeremy Hughes; Reiko Inagi; Celia Jenkinson; Vivekanand Jha; Mikio Kato; Darren Kelly; Jeffrey Kopp; Ron Korstanje; Romaldas Mačiulaitis; Patrick B. Mark; Hans-Peter Marti; Stephen P. McAdoo; Jeffrey H. Miner; Alberto Ortiz; Samir M. Parikh; Ambra Pozzi; Paola Romagnani; Pierre Ronco; Brad H. Rovin; Julio Saez-Rodriguez; Moin A. Saleem; John A. Sayer; Stuart Shankland; Andrey S. Shaw; Maria José Soler; Yusuke Suzuki; Tomoko Takano; Sydney Tang; Rene Tolba; Ifeoma Ulasi; John Viel; Yoshihisa Yamada; Motoko Yanagita; Takashi Yokoo; Nobuya Yoshida; Darren Yuen; Roy Zent; Aihua Zhang
• Keywords: Translational Research; Nephrology; Drug Development; Preclinical research; Animal model; Translational Science

Preclinical tests in animal models are key steps early drug development. Consequently, the International Society of Nephrology held a consensus meeting that connected experts global kidney community order to provide guidance on optimal management translational studies for development new drugs treat disease, entitled "TRANSFORM; TRAnslational Science FOR Medications." The covered various themes, including following: (i) selection disease model; (ii) pharmacokinetics; (iii) interventions late preclinical models; (iv) choice animal; (v) statistical power; (vi) organoids and organ-on-a-chip (vii) reporting results. This is first be provided conduct disease. These recommendations designed accelerate efficacious treatment diseases, improve prognosis quality life patients with variety diseases.